Agricultural Biologicals Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The agricultural biologicals testing market size was valued at USD 2.9 billion in 2025 and estimated to grow from USD 3.37 billion in 2026 to reach USD 7.09 billion by 2031, at a CAGR of 16.09% during the forecast period (2026-2031). This report is Segmented by Product Type (Biopesticides, and More), Application (Field Support, and More), Crop Type (Cereals and Grains, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Agricultural Biologicals Testing Market Trends and Insights

Expansion of Organic Farming Acreage

Organic acreage continues to grow at a faster rate than conventional land, and certification bodies now require multi-season field trials, residue analytics, and soil microbiome studies before approving biological inputs. The United States National Organic Program has intensified residue surveillance, which requires laboratories to integrate advanced chromatographic and molecular workflows. Europe’s organic scheme mirrors these testing demands and adds blockchain traceability, compelling labs to upgrade digital infrastructure. Field trials are conducted across diverse climatic zones to capture variability, thereby increasing testing volume over two to three harvests. Premium pricing for organic-certified products offsets the elevated testing spend, creating a durable funding loop for laboratory services. As regulators tighten organic input lists, manufacturers rely on independent Good Laboratory Practice (GLP) data to protect product positioning in lucrative organic channels.

Stringent Global Regulations Favoring Biologicals

The Environmental Protection Agency now requires molecular characterization and comprehensive toxicology for biochemical pesticides, while China’s Institute for the Control of Agrochemicals, Ministry of Agriculture (ICAMA), has adopted parallel microbial registration protocols. This convergence harmonizes fundamental data packages but raises documentation thresholds, favoring large GLP-certified providers. Post-market surveillance clauses extend testing well beyond launch, creating recurring laboratory revenue. Mutual recognition of data within selected trade blocs prevents full duplication, yet still necessitates region-specific residue and environment studies. Accelerated review lanes reward dossiers that include exhaustive analytics, pushing sponsors to invest in premium lab partners from the outset. The net effect is a larger, more predictable testing pipeline anchored to long-term regulatory compliance.

Lack of Harmonized Biological Testing Guidelines

Regulatory fragmentation forces companies to repeat studies for each jurisdiction, multiplying cost and time. Disagreements over statistical endpoints and environmental safety benchmarks slow Organisation for Economic Co-operation and Development (OECD) harmonization efforts, particularly for RNA-based pesticides. Emerging markets often publish draft guidelines without enforcement clarity, deterring early testing investments. Smaller firms face disproportionate burdens, as parallel programs exhaust limited capital and personnel. Until standard terms and endpoints converge, laboratories must tailor protocols for every submission, reducing economies of scale and extending development cycles.

Other drivers and restraints analyzed in the detailed report include:

• Rising Consumer Demand for Residue-Free Food
• Accelerated Research and Development Investments by Agro-Chemical Majors
• High Cost and Duration of Multi-Location Field Trials

Segment Analysis

The biopesticide segment held 43.62% agricultural biologicals testing market share in 2025, supported by mature regulatory frameworks and standardized GLP protocols. The agricultural biologicals testing market size associated with biopesticide registration is projected to keep rising through 2031 as microbial, botanical, and RNA-based products move through pipelines. Laboratories capitalize on established demand patterns, enabling predictable scheduling and utilization rates. Biofertilizers captured a 27.68% share as soil health gained global attention under EU Regulation 2019/1009. Growing clarity around biostimulant definitions propels that category to the fastest 17.15% CAGR, with test menus expanding into plant metabolomics and gene expression profiling. Labs are diversifying into these niches ahead of impending regulatory milestones that should unlock incremental volume.

Coupled with regulatory harmonization, product-type diversification buffers laboratories against cyclicality. Equipment amortization is spread across assay types, and cross-training scientists allows flexible staffing. As RNA-interference products approach launch, demand grows for molecular assays that verify mode of action and off-target effects, deepening service complexity and revenue per study.

Complete Report Scope:

• By Product Type
  • Biopesticides
  • Biofertilizers
  • Biostimulants
  • Other Product Types
• By Application
  • Field Support
  • Regulatory
  • Analytical
  • Other Applications
• By Crop Type
  • Cereals and Grains
  • Fruits and Vegetables
  • Oilseeds and Pulses
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East
    • Turkey
    • Saudi Arabia
    • Rest of Middle East
  • Africa
    • South Africa
    • Kenya
    • Rest of Africa

Geography Analysis

The Asia-Pacific region is the fastest-growing, with a 16.12% CAGR through 2031, as China enforces molecular data requirements for every microbial pesticide under its Association of Southeast Asian Nations (ICAMA) rules and Japan rolls out RNA-interference test protocols that necessitate advanced molecular diagnostics. China’s vast acreage generates steady demand because both domestic and multinational firms must run local trials to register new strains, while India’s organic acreage is expanding more than 12% each year and drives additional efficacy studies for certification bodies. South Korea is pairing biological inputs with smart-farm sensors, so laboratories there are upgrading data platforms that plug directly into Internet of Things dashboards. Lower labor costs also enable Asian testing companies to run large, multi-location trials at prices that undercut many Western providers. A nascent Association of Southeast Asian Nations (ASEAN) harmonization effort is underway to align study templates, which is expected to reduce regulatory friction across Southeast Asia over the next few years.

North America still holds the largest revenue share, at nearly 34.68% in 2025, as more than 200 GLP-certified facilities already cover the full spectrum of biological assays. A common template adopted by the United States Environmental Protection Agency and Canada’s est Management Regulatory Agency (PMRA) now saves sponsors up to 20% in duplicative study spend while keeping scientific rigor intact. Mexico’s export growers are sending testing volumes up 18% annually as they pursue residue-free certificates for shipments to the United States and Europe. Artificial-intelligence tools embedded in many United States labs cut data-review time by roughly one-quarter, freeing capacity for novel microbial containment studies. The region also benefits from strong university partnerships that pilot next-generation protocols before they spread worldwide.

Europe advances as Regulation 2019/1009 delivers the world’s most detailed roadmap for biostimulant testing. Germany and France account for more than 40% of regional revenue thanks to large farming sectors and strict compliance cultures. The United Kingdom’s post-Brexit rules set forces dual submissions, adding roughly 10% in extra study work for products sold on both sides of the Channel. Digital product passport rules that take effect later in the decade will require blockchain-ready test files, a shift that favors labs with sophisticated data infrastructure. Green Deal incentives and specialty hubs such as the Netherlands for greenhouse crops keep the regional pipeline full even as climatic zones vary widely across the continent.

List of Companies Covered in this Report:

• Eurofins Scientific SE
• SGS SA
• Intertek Group plc
• Bureau Veritas SA
• ALS Limited
• Syntech Research Group
• Staphyt SA
• Anadiag Group
• i2LResearch Ltd. (Cawood Scientific Limited)
• Fera Science Ltd. (Bridgepoint Group plc)
• RJ Hill Laboratories Ltd.
• LAUS GmbH
• Bionema Ltd.
• Biotecnologie B.T. Srl

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support